Dyadic International, Inc. entered into a Research, License, and Collaboration Agreement for the manufacture of therapeutic protein candidates using its C1 platform with Janssen Biotech, Inc. on December 16, 2021. Pursuant to Section 12.3 of the Agreement, on October 2, 2023, Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of December 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | -6.33% | -15.91% | -8.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.07% | 43.27M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- DYAI Stock
- News Dyadic International, Inc.
- Janssen Biotech, Inc. Terminates Research, License, and Collaboration Agreement with Dyadic International, Inc